[Comment] Expression of Concern: Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Journal content Created on 23 Jun 2026 The Lancet

• Details
• • All feed content
  • My feed content